Julian Jamie Freen-van Heeren

21PUBLICATIONS
15CO-AUTHORS
Molecular targetsEpigenetics (incl. genome methylation and epigenomics)Innate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Dec 11, 2025
From Spike to Strike: SARS-CoV-2 mRNA Vaccines Sensitise Tumours to PD-1/PD-L1 Blockade.

Julian Jamie Freen-van Heeren

|Nov 14, 2025
Building tolerance: employing genome engineering toward universal Treg therapy.

Julian J Freen-van Heeren

|Mar 12, 2025
Age and Latent Cytomegalovirus Infection Do Not Affect the Magnitude of De Novo SARS-CoV-2-Specific CD8+ T Cell Responses.

Jet van den Dijssel, Veronique A L Konijn, Mariël C Duurland

|Feb 27, 2024
Broad-spectrum defenders: γδ T cells take on a multitude of immune challenges.

Julian J Freen-van Heeren

|Feb 17, 2023
Age is just a number: long-lasting T-cell immunity can span several lifetimes.

Julian J Freen-van Heeren, Rianne Opstelten

|Dec 09, 2022
Memory CD8+ T cells upregulate glycolysis and effector functions under limiting oxygen conditions.

Ammarina Beumer-Chuwonpad, Floris P J van Alphen, Natasja A M Kragten

Pageof 4